Who is developing what with whom, per the filing. In its annual report for fiscal 2020, filed February 16, 2021, CRISPR Therapeutics describes its most advanced program, CTX001, as a gene-editing candidate it is developing in collaboration with Vertex Pharmaceuticals. The structure matters more than the headline: this is a partnered asset, not a wholly owned one.
For a company whose value sits heavily on a single lead program, the collaboration framing is the load-bearing disclosure. A shared development-and-commercialization arrangement means the upside is split — and that the partner carries weight in decisions about how the program advances. The 10-K presents CTX001 as still in clinical development, not as an approved product.
The deals-desk read is to separate ambition from cash. The partnership de-risks the program financially — a larger, well-capitalized partner shares the cost of an expensive, novel modality — but it also means CRISPR does not capture the full economics of any eventual success. That trade-off is the essence of the arrangement as the filing lays it out.
Read forward from early 2021, the open question is execution: whether a clinical-stage, partnered gene-editing candidate can move through development toward approval, and what the shared structure ultimately delivers to each side. The 2020 10-K does not answer that — it documents the partnership as it stands at the time of filing.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.